ApoA1 Antibody

Product Specifications

Background

ApoA1 Antibody: Apolipoprotein A1 (ApoA1) is the major protein component of high density lipoprotein (HDL) in plasma, which is correlated with cardiovascular disease. ApoA1 is synthesized in the liver and small intestine and promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterolacyltransferase (LCAT), the enzyme responsible for the formation of most plasma cholesteryl esters. Defects in ApoA1 are associated with HDL deficiency, Tangier disease, and systemic non-neuropathic amyloidosis.

NCBI Gene ID

335

Swiss Prot

P02647

Accession Number

P02647

Host

Rabbit

Reactivity

Human, Chicken

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Cancer, Cell Cycle

Purification

ApoA1 Antibody is affinity chromatography purified via peptide column.

Positive Control

Chicken Liver Lysate

Concentration

1 mg/mL

Buffer

ApoA1 Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

ApoA1 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Fragment

IgG

Symbol

APOA1

NCBI Official Name

Apolipoprotein A-I

NCBI Organism

Homo sapiens

Background Reference 01

Zhu X, Wu G, Zeng W, et al. Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties. J. Lipid Res. 2005; 46:1303-11

Background Reference 02

Sorci-Thomas MG, Prack MM, Dashti N, et al. Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A-I gene: relationship to plasma concentration of high density lipoproteins. J. Lipid Res. 1989; 30:1397-403

Background Reference 03

Lai C-Q, Parnell LD, and Ordovas JM. The APOA1 /C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr. Opin. Lipid. 2005; 16:153-66